Predictive Oncology enters standby equity purchase agreement with Yorkville

Predictive Oncology (POAI) has entered into a standby equity purchase agreement with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global. Predictive Oncology expects the partnership to provide an efficient and flexible source of funding, enabling the company to progress its ongoing drug discovery, biomarker discovery and drug repurposing initiatives, and business development opportunities with leading biopharmaceutical companies, leveraging its novel AI and machine learning capabilities. Under the terms of the agreement, Predictive Oncology has the right to sell, and Yorkville has the obligation to purchase up to $10M worth of the Company’s stock. Predictive Oncology, at its sole discretion, will control the timing and amount of all sales of common stock, and there are no warrants, derivatives, or other share classes associated with the SEPA. The Company is not obligated to utilize any of the $10M available under the SEPA and there are no minimum commitments or minimum use penalties. The SEPA does not impose any restrictions on the Company’s operating activities.